S-P's Claritin-D Approved In USA

21 November 1994

Competition is hotting up in the US antiallergy market with the news that Schering-Plough has received approval for its extended-release combination antihistamine/decongestant Claritin-D (loratadine 5mg and pseudophedrine sulfate 120mg). A launch for the product is expected towards the end of the month.

Claritin-D, which is indicated for the relief of symptoms of seasonal allergic rhinitis, is the second such combination product to be launched onto the market; the other is Marion Merrell Dow's Seldane-D (terfenadine and pseudoephedrine HCl) which was launched onto the market in the USA in August 1991 and had sales of $142 million last year. The worldwide allergy market is estimated at around $2 billion, with the USA accounting for 50% of the total market.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK



Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight